Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy

ConclusionsUnexpectedly, in our study, patients who had the shortest WP 0 –30 days had the most disease activity. Shortening WPs may not be enough to suppress disease activity post-natalizumab switch.

Source: Journal of Neurology - April 8, 2020 Category: Neurology Source Type: research